Navigation Links
Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference
Date:5/16/2008

HAE: TSX

MONTREAL, May 16 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX:HAE), a specialty bio-therapeutics company developing high-value human proteins for commercialization, announced today that its Chairman of the Board and Chief Executive Officer, Joseph Galli, will present at the upcoming Rodman & Renshaw 5th Annual Global Healthcare Conference on Tuesday, May 20, 2008 in the Zephyr Room at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco, beginning at 1:40 p.m Central European Summer Time (7:40 a.m. Eastern Daylight Time).

Rodman & Renshaw will webcast the audio portion of the presentation and post the associated slides via its website at http://www.rodmanandrenshaw.com, hosted by Wall Street Webcasting. To access the live broadcast via internet in listen-only mode, or the subsequently archived recording, simply cut and paste the following link directly into your web browser: http://www.wsw.com/webcast/rrshq13/hae.cn

Please visit the site at least five minutes prior to start time for instructions.

About Rodman & Renshaw's Annual Global Healthcare Conference

The conference will include presentations by over 200 companies, as well as experts from the medical, scientific and investment communities. Details regarding the conference can be obtained at http://www.rodmanandrenshaw.com

Haemacure also announced today the resignation of Mr. Neil Weiner from the Board of Directors of the Company. "On behalf of the Board and management team, I wish to thank Neil for his tremendous contribution and dedication to Haemacure" commented Joseph Galli, Chairman and CEO of Haemacure.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant planned to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medecine, drug delivery and combination with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.


'/>"/>
SOURCE HAEMACURE CORPORATION
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Haemacure Reports Third Quarter 2007 Results
2. Haemacure Adopts Strategy for "First-Patient-In" Fibrin Sealant Pivotal Clinical Trials
3. Haemacure announces webcast of presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conferencec
4. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
5. Media Invitation - Annual General and Special Meeting of Shareholders of Haemacure
6. Haemacure Reports on its annual general and special meeting of shareholders
7. Haemacure Discloses Positive Results of a preclinical study of its fibrin sealant in adhesion prevention and opens a new opportunity in a market with a significant unmet medical need
8. Haemacure to Present at the BioFinance 2008 Conference to be held at the Toronto Marriott Eaton Centre, May 6 - 8, 2008
9. Haemacure financing receives shareholder consent - Series B Warrants are amended
10. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
11. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2017)... ... 2017 , ... Norland at Swissray is pleased to announce the release of the ... ELITE DXA has an active scan window, which is more than double that of existing ... scan area could not undergo an accurate total body bone density or body composition study. ...
(Date:3/24/2017)... New York, NY (PRWEB) , ... March 24, ... ... a global scale; from third world countries to hospitals in the United States, ... sparks a conversation on the current obstacles facing infection prevention and offers strategies ...
(Date:3/24/2017)... ... March 24, 2017 , ... Texas Physical Therapy Specialists (TexPTS) is pleased ... Huebner Road. The clinic is the group’s 7th location in San Antonio and 23rd ... PT, will provide care from the clinic, which opened March 22, 2017. ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... its innovative EcoQube Frame vertical micro-veggies garden on Kickstarter . Surpassing the ... product – with nearly 2,000 consumers (and counting) already backing the campaign. ...
(Date:3/24/2017)... Westchester County, NY (PRWEB) , ... March 24, 2017 , ... ... in Somers and White Plains, N.Y., is pleased to announce Westchester resident Lauren C. ... as a law clerk for the firm, will concentrate her practice in elder law, ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... in St. Joseph, Missouri , has selected AccuReg to help standardize ... 22 cities, and its flagship St. Joseph Medical Center. Mosaic Life Care ... to its patients, including the insurance, billing and collections processes. ... ... Joseph Medical Center ...
(Date:3/23/2017)... , March 23, 2017  Transportation Insight, a multi-modal ... end-to-end supply chain management firm with expertise serving clients ... Solutions Rick Zaffarano was named a 2017 ... Supply Chain by the only publication exclusively dedicated to ... supply chain. "Rick has brought to Transportation ...
(Date:3/23/2017)... -- As a result of diagnostic technology increasing ... allergic diseases, cutting edge developments in targeted drugs ... in which pharmaceutical and biotech companies are addressing ... both a high quality meeting and a platform ... research scholars and doctors. The event will also ...
Breaking Medicine Technology: